In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

New and existing investors put $77mm into Merrimack's Series G round

Executive Summary

Cancer company Merrimack Pharmaceuticals Inc. raised $77mm from 61 new and existing backers in its Series G round. Participants included Credit Suisse First Boston Next Fund, Crocker Ventures, funds associated with Fred Alger Management, funds managed by Noonday Asset Management, Jennison Associates, TPG-Axon Capital, and WT Investment Advisors Fund.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies